Serum Institute of India
| Institution is active | |
| Legal form | Private Company Limited |
| Founder | Cyrus Sooli Poonawalla |
| Founding date | 1966 |
| Headquarters | Pune, Maharashtra, India |
| Website | https://www.seruminstitute.com/ |
Connections
Serum Institute of India
- Financial funding -
Bill & Melinda Gates Foundation
In October 2020, the Serum Institute of India received $ 4,000,000 funding from the Bill and Melinda Gates Foundation.
Specified purpose of the funding: to support r & d for covid-19 response
Specified purpose of the funding: to support r & d for covid-19 response
Serum Institute of India
-
UNICEF
No information yet.
Serum Institute of India
-
AstraZeneca
The Serum Institute of India (SII) and Astrazeneca have made a license agreement to deliver a billion doses by the University of Oxford's vaccine candidate against Covid-19 to countries with medium and low incomes, including India. By the end of 2020, both companies have undertaken to provide 400 million cans, said Astraza in a statement on June 4th, 2020.
Press release from AstraZeneca
https://www.astranceca.com/media-centre/press-releases/2020/astrzenceca-takes-next-tovs-towards-and- and
Press release from AstraZeneca
https://www.astranceca.com/media-centre/press-releases/2020/astrzenceca-takes-next-tovs-towards-and- and
Serum Institute of India
-
Cyrus Sooli Poonawalla
No information yet.
Serum Institute of India
-
Adar C. Poonawalla
No information yet.
Serum Institute of India
- Agreement on the production of Sputnik V -
RDIF
On July 13, 2021, the RDIF announced that it had reached an agreement with the Serum Institute of India regarding the production of the Sputnik V vaccine, which was developed in Russia.
The SII is expected to produce 300 million doses of the vaccine annually.
The SII is expected to produce 300 million doses of the vaccine annually.
WiKipedia [* muss spezifiziert werden *]
Serum Institute of India
-
Sputnik V
The Russian State Fund and the Serum Institute of India have announced plans to start the production of the Sputnik-V vaccine in India.
The first batch of the Sputnik-V vaccine is expected to be produced in the institutions of the Serum Institute from September.
They intend to produce over 300 million doses of the vaccine in India.
As part of the technology transfer process, SII has already received cell and vector rehearsals from the Gamaleya Center.
With the approval of the import of the Drug Controller General of India, the cultivation process has also started.
13-07-2021
The first batch of the Sputnik-V vaccine is expected to be produced in the institutions of the Serum Institute from September.
They intend to produce over 300 million doses of the vaccine in India.
As part of the technology transfer process, SII has already received cell and vector rehearsals from the Gamaleya Center.
With the approval of the import of the Drug Controller General of India, the cultivation process has also started.
13-07-2021
Serum Institute of India
- License agreement -
Novavax
Commercial license agreement between Novavax and the Serum Institute of India (SII) on the use of the proprietary Matrix-M ™-vaccine adjuvan from Novavax at the malaria vaccine candidate from the Serum Institute of India.
Serum Institute of India
- Manufacturer -
MenAfriVac
No information yet.